^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ID-LV305
i
Other names: ID-LV305, DCvex-NY-ESO-1, LV 305, LV305, NY-ESO-1 cancer vaccine, DCVex/NY-ESO-1 cancer vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Merck (MSD)
Drug class:
Immunostimulant, NY ESO 1 inhibitor, Dendritic cell activator
Related drugs:
8ms
NCI-2018-00926: Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma (clinicaltrials.gov)
P1, N=15, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
Trial completion • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
|
cyclophosphamide • Proleukin (aldesleukin) • CMB305 • ID-LV305
2years
NCI-2018-00926: Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma (clinicaltrials.gov)
P1, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2021 --> Dec 2022
Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
|
Proleukin (aldesleukin) • CMB305 • ID-LV305
3years
Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma (clinicaltrials.gov)
P1, N=15, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Dec 2021
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
|
Proleukin (aldesleukin) • CMB305 • ID-LV305 • cyclophosphamide intravenous
Share via
